Azitra, Inc.AZTREarnings & Financial Report
Azitra, Inc. is a clinical-stage biotechnology company focused on developing innovative dermatology therapies. It leverages proprietary protein engineering platforms to create treatments for common and rare skin conditions including atopic dermatitis, psoriasis, and genetic skin disorders, primarily serving the North American biopharmaceutical market.
AZTR Q3 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-2.8M
Net Profit
$-2.8M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.67
Azitra, Inc. Q3 FY2025 Financial Summary
Azitra, Inc. reported revenue of $0 for Q3 FY2025, with a net profit of $-2.8M (down 173.9% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-2.8M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2025 |
Azitra, Inc. Annual Revenue by Year
Azitra, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $7.5K).
Azitra, Inc. Quarterly Revenue & Net Profit History
Azitra, Inc. results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $0 | — | $-2.8M | N/A |
| Q2 FY2025 | $0 | — | $-2.9M | N/A |
| Q4 FY2024 | $0 | — | N/A | N/A |
| Q3 FY2024 | $0 | — | $-1.0M | N/A |
| Q2 FY2024 | $7.5K | -95.6% | $-2.6M | -35093.2% |
| Q1 FY2024 | $0 | — | $-2.9M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $7500 | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | -95.6% | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Assets | $6.1M | $3.9M | $9.8M | $7.4M | $4.0M | $4.3M |
| Liabilities | $1.7M | $2.2M | $1.7M | $1.7M | $1.7M | $2.0M |
| Equity | $4.3M | $1.7M | $8.1M | $5.7M | $2.2M | $2.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Operating CF | $-3.0M | $-2.1M | $-2.5M | $-10.2M | $-2.8M | $-2.4M |